HBM Healthcare Investments successfully issued CHF 100 million 1.125 per cent Bonds due 2027. The bonds will be admitted for trading and listing on the SIX Swiss Exchange. The advisors Homburger acted as counsel to HBM Healthcare Investments in this matter. The Homburger team was led by partner Hansjürg Appenzeller (capital markets, pictured) and included partner Stefan Oesterhelt (tax), associate Daniel Junginger and paralegal Ganna Schneuwly (both capital markets). Helvetische Bank and […]
Biopharmaceutical company Relief Theraputics Holding, has a binding agreement with two institutional U.S. investors completed. The contract provides for the purchase of Relief shares with a total value of CHF 15 million, which come from
UBS Group completed its issuance of USD 2 billion in aggregate principal amount of fixed rate/fixed rate senior notes due August 2027 under its senior debt programme. The notes are bail-inable (TLAC) bonds that are eligible
UBS, acting through its London branch, successfully completed its issuance of (i) USD 1 bn aggregate principal amount of Floating Rate Notes due August 2024, and (ii) USD 1 bn aggregate principal amount of 0.70 per cent. Notes due
Credit Suisse launched and completed, its registered offering of USD 3.75 bn aggregate principal amount of senior notes. The offering consisted of USD 1.4 billion aggregate principal amount of 0.520% senior notes due 2023, USD 1.75 billion aggregate principal amount
Niederer Kraft Frey (NKF) has advised Digital Realty, a global provider of carrier- and cloud-neutral data center, colocation and interconnection solutions on the offering of CHF 275 million of 0.20 percent bonds due 2026 and CHF 270 million of 0.55
Relief Therapeutics Holding, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, has issued 1,000,000,000 additional registered shares out of the authorised share capital approved by the Annual
H.C. Wainwright acted as sole placement agent in connection to the private placement of 71,428,572 shares in Relief Therapeutics Holding, a Swiss biopharmaceutical company listed at SIX Swiss Exchange, at a price of CHF 0.21 per
Baker McKenzie has advised Société Générale and SG Issuer on the establishment of their first Swiss Structured Securities Issuance Program. The Program has been prepared in compliance with the new prospectus regime,
Homburger acted as legal counsel to UBS on its issuance of its inaugural green bonds, consisting of EUR 500 million, due June 2026. Along with CHF 250 million in aggregate principal amount of 0.150 per cent, due June 2028). senior
